

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Glioblastoma	Gremlin 1 (GREM1)	<i>In vitro</i> and mouse studies suggest inhibiting GREM1 could help treat glioblastoma. In human glioma cancer stem cells (CSCs), expression of the bone morphogenetic protein (BMP) antagonist GREM1 was greater than that in glioma non-CSCs. In human glioma CSCs, GREM1 suppressed BMP2-mediated inhibition of proliferation. In mice receiving an intracranial injection of human CSCs, <i>GREM1</i> -targeted shRNA prevented tumor formation and increased survival compared with nontargeted shRNA. Next steps could include screening for a pharmacological GREM1 inhibitor.	Patent and licensing status unavailable	Yan, K. <i>et al. Genes Dev.</i> ; published online May 1, 2014; doi:10.1101/gad.235515.113 Contact: Jeremy N. Rich, Cleveland Clinic, Cleveland, Ohio e-mail: richj@ccf.org
		SciBX 7(23); doi:10.1038/scibx.2014.675 Published online June 12, 2014		